Showing results (1111-1120 of 1,165) with videos related to
Sort By:
Pageof 117
JACC. Heart Failure|March 7, 2023
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction SpectrumJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|February 5, 2019
Antibiotic management of acute pharyngitis in primary care, A M W Chan, W W Y Au, et al.Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.European Journal of Heart Failure|March 6, 2024
Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: Insights from the STRONG-HF trialMatteo Pagnesi, Oscar Alberto Gomez Vilamajó, Alejandro Meiriño, et al.European Journal of Heart Failure|January 3, 2024
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, Theresa A McDonagh, Marco Metra, et al.Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 28, 2021
Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary diseaseGiuseppe Vergaro, Alberto Aimo, James L Januzzi, et al.European Journal of Heart Failure|October 19, 2017
Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of CardiologyThomas M Gorter, Dirk J van Veldhuisen, Johann Bauersachs, et al.Lancet (London, England)|September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaiez Zannad, Christopher M O'Connor, Javed Butler, et al.Circulation|November 19, 2019
Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFJohn J V McMurray, Alice M Jackson, Carolyn S P Lam, et al.Global Heart|November 16, 2022
Correction: Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 StudyDorairaj Prabhakaran, Kavita Singh, Dimple Kondal, et al.Pageof 117